GlobalData on MSN17h
Takeda announces appointment of Julie Kim as CEO
Takeda has announced the appointment of Julie Kim as successor to Christophe Weber, its current president, CEO and ...
Takeda Pharmaceutical Co.: Hold Rating Amid Mixed Q3 Results, Upward Guidance Revision, and Strategic Moves
Miki Sogi, an analyst from Bernstein, maintained the Hold rating on Takeda Pharmaceutical Co (TKPHF – Research Report). The associated price ...
Takeda gains after FY24 guidance raise, CEO transition
Takeda (TAK) stock rose in premarket trading after raising its full-year outlook and appointing Julie Kim as the next CEO.
BioSpace12h
Takeda Drops Epilepsy Drug, Names New CEO Amid Q3 Earnings
Analysts were unfazed by the news that Takeda will cease development of soticlestat after Phase III failures, while ...
FierceBiotech21h
Takeda axes failed epilepsy asset after FDA weighs in on data package
Takeda has axed plans to seek approval for its failed epilepsy drug candidate soticlestat. The Japanese drugmaker pulled the ...
ThePrint4h
Celebrating the Legacy of Excellence and Innovation, Zydus Takeda Healthcare marks 25 years of manufacturing operations in India
India], January 31: Zydus Takeda Healthcare Private Limited (ZTHPL), a joint venture company set up by Zydus Lifesciences ...
Takeda 9-Month EPS Rises, Revises FY24 Outlook, Julie Kim To Be New CEO
Concurrently, the company also announced the decision to appoint Julie Kim as the Chief Executive Officer, succeeding Christophe Weber, who plans to retire from the position in June 2026. Kim ...
Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth
Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended ...